GlassScriptPhysician profile
Eryn Mcmichael
NPI 1225788870
$5,403.91
in general payments reported to CMS, 2019-2025
48 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.55 · 2022: $851 · 2023: $1,025 · 2024: $2,378 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,022 · Education: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,022.41 |
| Education | $453.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $921.26 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Novartis Pharmaceuticals Corporation | $522.94 | 2024-2025 | |
| Genzyme Corporation | $341.12 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $325.80 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Incyte Corporation | $323.89 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Exelixis INC. | $215.01 | 2024-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $207.17 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $194.27 | 2022-2024 | Alunbrig, Iclusig, Vpriv |
| Rigel Pharmaceuticals, INC. | $151.69 | 2022-2024 | Tavalisse, Rezlidhia |
| Beigene USA, INC. | $144.42 | 2023-2024 | Brukinsa |
| Beone Medicines USA, INC. | $139.76 | 2025 | Tevimbra, Brukinsa |
| Adc Therapeutics America, INC. | $129.18 | 2023-2024 | |
| Pfizer INC. | $123.36 | 2023-2024 | |
| Daiichi Sankyo INC. | $121.55 | 2024-2025 | Enhertu |
| Lilly USA, LLC | $99.87 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $98.33 | 2024 | Orgovyx |
| Genentech USA, INC. | $94.50 | 2024-2025 | Tecentriq, Tecentriq Hybreza, Polivy |
| Astellas Pharma US INC | $90.57 | 2024-2025 | Padcev, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $74.32 | 2024 | |
| Celgene Corporation | $69.16 | 2023-2024 | Pomalyst, Opdualag |
| Regeneron Healthcare Solutions, INC. | $67.14 | 2023-2024 | Libtayo |
| Eisai INC. | $66.28 | 2025 | |
| Novocure INC. | $66.05 | 2022 | |
| Seagen INC. | $60.35 | 2022-2023 | Adcetris, Tukysa |
| Puma Biotechnology, INC. | $55.40 | 2022-2024 | |
| Array Biopharma INC | $48.14 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $47.98 | 2022 | |
| Amgen INC. | $44.85 | 2023 | Kyprolis, Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $44.76 | 2022-2025 | |
| G1 Therapeutics, INC. | $43.91 | 2023 | Cosela |
| Janssen Pharmaceuticals, INC | $42.35 | 2023-2024 | Xarelto |
| Tersera Therapeutics LLC | $41.50 | 2024-2025 | Xermelo, Zoladex |
| Bard Peripheral Vascular, INC. | $38.66 | 2025 | Trek |
| Abbvie INC. | $36.24 | 2023 | |
| Aveo Pharmaceuticals, INC. | $34.91 | 2024 | |
| Genmab U.S., INC. | $33.80 | 2025 | Epkinly |
| Teleflex LLC | $28.07 | 2024 | Arrow |
| Emd Serono, INC. | $24.73 | 2024 | |
| Coherus Oncology, INC. | $24.12 | 2024 | |
| Glaxosmithkline, LLC. | $23.92 | 2024 | Ojjaara |
| Pharmaessentia USA Corporation | $23.10 | 2022 | |
| Dendreon Pharmaceuticals LLC | $20.73 | 2022 | |
| Legend Biotech USA INC. | $19.40 | 2025 | Carvykti |
| Pharmacosmos Therapeutics INC. | $16.95 | 2023 | Monoferric |
| Alnylam Pharmaceuticals INC. | $16.87 | 2024 | Givlaari |
| Alexion Pharmaceuticals, INC. | $16.64 | 2024 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $14.63 | 2022 | |
| Foundation Medicine, INC. | $14.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eryn Mcmichael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.